Complement regulatory proteins and autoimmunity

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 5, 2000, Pages 367-372

  Kawano, Mitsuhiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Complement receptor type l (cd35); Decay accelerating factor (cd55); Homologous restriction factor (cd59); Membrane cofactor protein (cd46)

Indexed keywords

CD46 PROTEIN, HUMAN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; LEUKOCYTE ANTIGEN; MEMBRANE COFACTOR PROTEIN; MEMBRANE PROTEIN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; COMPLEMENT ACTIVATION; HUMAN; REVIEW;

ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; AUTOIMMUNE DISEASES; AUTOIMMUNITY; COMPLEMENT ACTIVATION; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, COMPLEMENT 3B;

EID: 0034571291     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. ATKINSON J. P. and FARRIES T. (1987): Separation of self from non-self in the complement system. Immunol. Today, 8, 212-215.
2. BARDENSTEIN D. S., DIETZ Y., LASS J. H. and MEDOF M. E. (1994): Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland. Curr. Eye Res., 13, 851-855.
3. BJORGE L., JENSEN T. S., ULVESTAD E., VEDELER C. A. and MATRE R. (1995): The influence of tumor necrosis factor-α, interleukin-lβ and interferon-γ on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scand. J. Immunol., 41, 350-356.
4. BRASOVEANU L. I., FONSATTI E., VISINTIN A., PAVLOVIC M., CATTAROSSI I., COLIZZI F., GASPAROLLO A., CORAL S., HOREISI V., ALTOMONTE M. and MAIO M. (1997): Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J. Clin. Invest, 100, 1248-1255.
5. CHEUNG N. V., WALTER E. I., SMITH-MENSAH W. H., RATNOFF W. D., TYKOCINSKI M. L. and MEDOF M. E. (1988): Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest, 81, 1122-1128.
6. CHRISTIANSEN D., MILLAND J., THORLEY B. R., MCKENZIE I. F. C. and LOVELAND B. E. (1996): A functional analysis of recombinant soluble CD46 in vivo and a comparison with rec-ombinant soluble forms of CD55 and CD35 in vitro. Eur. J. Immunol., 26, 578-585.
7. COLE J. L., HOUSLEY G. A. JR., DYKMAN T. R., MACDERMOTT R. P. and ATKINSON J. P. (1985): Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc. Natl. Acad. Sci. USA, 82, 859-863.
8. CUIDA M., LEGLER D. W., EIDSHEIM M. and JONSSON R. (1997): Complement regulatory proteins in the salivary glands and saliva of Sjögren's syndrome patients and healthy subjects. Clin. Exp. Rheumatol., 15, 615-623.
9. DAVIES A., SIMMONS D. L., HALE G., HARRISON R. A., TIGHE H., LACHMANN P. J. and WALDMANN H. (1989): CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med., 170, 637-654.
10. DAVIES M. E., HORNER A., LOVELAND B. E. and MCKENZIE I. F. C. (1994): Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease. Scand. J. Rheumatol., 23, 316-321.
11. DEVITT A., MOFFATT O. D., RAYKUNDALIA C., CAPRA J. D., SIMMONS D. L. and GREGORY C. D. (1998): Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature, 392, 505-509.
12. ENDOH M., YAMASHINA M., OHI H., FUNAHASHI K., IKUNO T., YASUGI T., ATKINSON J. P. and OKADA H. (1993): Immunohis-tochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin. Exp. Immunol., 94, 182-188.
13. FALK R. J., DALMASSO A. P., KIM Y., LAM S. and MICHAEL A. (1985): Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N. Engl. J. Med., 315, 1584-1589.
14. GARWRYL M. A., CHUDWIN D. S., LONGLOIS P. F. and LINT T. F. (1988): The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum., 31, 188-195.
15. GAUTHIER V. J. and EMLEN J. W. (1997): Immune complexes in systemic lupus erythematosus. In WALLACE D. J. and HAHN B. H.: Dubois' lupus erythematosus. 5th ed. Williams & Wilkins, Baltimore-Philadelphia-London-Paris-Bangkok-Buenos Aires-Hong Kong-Munich-Sydney-Tokyo-Wroclaw, 207-220.
16. GUC D., GULATI P., LEMERCIER C., LAPPIN D., BIRNIE G. D. and WHALEY K. (1993): Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium. Rheumatol. Int., 13, 139-146.
17. HARA T., KURIYAMA S., KIYOHARA H., NAGASE Y., MATSUMOTO M. and SEYA T. (1992): Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects. Clin. Exp. Immunol., 89, 490-494.
18. HEBERT L. A. (1987): Clearance of immune complexes from the circulation of man and other primates. Am. J. Kidney Dis., 17, 352-361.
19. JANEWAY C. A. JR. (1992): The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today, 13, 11-16.
20. JARVA H. and MERI S. (1999): Paroxysmal nocturnal haemoglobinuria: the disease and a hypothesis for a new treatment. Scand. J. Immunol., 49, 119-125.
21. JONES J., LAFFAFIAN I., COOPER A. M., WILLIAMS B. D. and MORGAN B. P. (1994): Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br. J. Rheumatol., 33, 707-712.
22. JONES J. and MORGAN B. P. (1995): Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Immunology, 86, 651-660.
23. KAWANO M., SEYA T., KONI I. and MABUCHI H. (1999): Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol., 116, 542-546.
24. KAWANO M. TSUNODA S., KONI I, MABUCHI H., MURAMOTO H., YACHIE A. and SEKI H. (1997): Decreased expression of 20-kD homologous restriction factor (HRF20, CD59) on T lymphocytes in Epstein-Barr virus (EBV)-induced infectious mononucleosis. Clin. Exp. Immunol., 108, 260-265.
25. KENNEDY S. P., ROLLINS S. A., BURTON W. V., SIMS P. J., BOTHWELL A. L. M., SQUINTO S. P. and ZAVOICO G. B. (1994): Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation, 57, 1494-1501.
26. LEHTO T., HONKANEN E., TEPPO A. M. and MERI S. (1995): Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int., 47, 1403-1411.
27. MASON J. C., YARWOOD H., SUGARS K., MORGAN B. P., DAVIES K. A. and HASKARD D. O. (1999): Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood, 94, 1673-1682.
28. MATSUI H., TSUJI S., NISHIMURA H. and NAGASAWA S. (1994): Activation of the alternative pathway of complement by apoptotic Jurkat cells. FEBS Lett., 351, 419-422.
29. MEDOF M. E., WALTER E. I., RUTGERS J. L., KNOWLES D. M. and NUSSENZWEIG V. (1987): Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med., 165, 848-864.
30. MERI S., MATTILA P. and RENKONEN R. (1993): Regulation of CD59 expression on human endothelial cell line E. A. by 926. Eur. J. Immunol., 23, 2511-2516.
31. MORAN P., BEASLEY H., GORRELL A., MARTIN E., GRIBLING P., FUCHS H., GILLETT N., BURTON L. E. and CARAS I. W. (1992): Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J. Immunol., 149, 1736-1743.
32. MORGAN B. P. (1989): Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effect. Biochem. J., 264, 1-14.
33. NANGAKU M., MEEK R. L., PIPPIN J., GORDON K. L., MORGAN B. P., JOHNSON R. J. and COUSER W. G. (1996): Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Kidney Int., 50, 257-266.
34. NICHOLSON-WELLER A., BURGE J., FEARON D. T., WELLER P. F. and AUSTEN K. F. (1982): Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. J. Immunol., 129, 184-189.
35. NOSE M., KATOH M., OKADA N., KYOGOKU M. and OKADA H. (1990): Tissue distribution of HRF 20, a novel factor prevent-ing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology, 70, 145-149.
36. PASCH M. C., BOS J. D., DAHA M. R. and ASGHAR S. S. (1999): Transforming growth factor-beta isoforms regulate the surface expression of membrane cofactor protein (CD46) and CD59 on human keratinocytes. Eur. J. Immunol., 29, 100-108.
37. ROITT I. M. (1997): Roitt's essential immunology. 9th ed. Blackwell Science, London, 3-21.
38. ROONEY I. A., DAVIES A., GRIFFITHS D., WILLIAMS J. D., DAVIES M., MERI S., LACHMANN P. J. and MORGAN B. P. (1991): The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin. Exp. Immunol., 83, 251-256.
39. RONNEY I. A. and MORGAN B. P. (1992): Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology, 76, 541-547.
40. SAVILL J., FADCK V., HENSON P. and HASLETT C. (1993): Pahgocyte recognition of cells undergoing apoptosis. Immunol. Today, 14, 131-136.
41. SCHMITT C. A., SCHWAEBLE W., WITTIG B. M., MEYER zum BUSCHENFELDE K. H. and DIPPOLD W. G. (1999): Expression and regulation by interferon-gamma on the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur. J. Cancer, 35, 117-124.
42. SCHUR P. H. (1997): Complement and systemic lupus erythematosus. In WALLACE D. J. and HAHN B. H.: Dubois' lupus erythematosus. 5th ed. Williams & Wilkins, Baltimore-Philadelphia-London-Paris-Bangkok-Buenos Aires-Hong Kong-Munich-Sydney-Tokyo-Wroclaw, 245-261.
43. SEYA T., HARA T., IWATA K., KURIYAMA S., HASEGAWA T., NAGASE Y., MIYAGAWA S., MATSUMOTO M., HATANAKA M. and ATKINSON J. P. (1995): Purification and functional properties of soluble forms of membrane cofactor protein (MCP, CD46) of complement: Identification of forms increased in cancer patients' sera. Int. Immunol., 7, 727-736.
44. SEYA T., HARA T., MATSUMOTO M., SUGITA Y. and AKEDO H. (1990): Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J. Exp. Med., 172, 1673-1680.
45. SEYA T., TURNER J. R. and ATKINSON J. P. (1986): Purification and characterization of a membrane protein (gp45-70) which is a cofactor for cleavage of C3b and C4b. J. Exp. Med., 163, 837-855.
46. SHIBATA T., COSIO F. G. and BIRMINGHAM D. J. (1991): Complement activation induces the expression of decay-acceleration factor on human mesangial cells. J. Immunol., 147, 3901-3908.
47. SUGITA Y., ITO K., SHIOZUKA K., SUZUKI H., GUSHIMA H., TOMITA M. and MASUHO Y. (1994): Recombinant soluble CD59 inhibits reactive hemolysis with complement. Immunology, 82, 34-41.
48. TAMAI H., MATSUO S., FUKATSU A., NISHIKAWA K., SAKAMOTO N., YOSHIOKA K., OKADA N. and OKADA H. (1991): Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study. Clin. Exp. Immunol., 84, 256-262.
49. TSUJI S., KAJI K. and NAGASAWA S. (1994): Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. J. Biochem., 116, 794-800.
50. + T cells Undergoing apoptosis in SLE and Sjögren's syndrome. Scand. J. Immunol., 51, 293-299.
51. UEHARA T., MIYAWAKI T:, OHTA K., TAMARU Y., YOKOI T., NAKAMURA S. and TANIGUCHI N. (1992): Apoptotic cell death of primed CD45RO+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis. Blood, 80, 452-458.
52. ZHANG H., Yu J., BAJWA E., MORRISON S. L. and TOMLINSON S. (1999): Targeting of functional antibody-CD59 fusion proteins to a cell surface. J. Clin. Invest., 103, 55-61.